| SEC FILE NUMBER | ||
| 000-29089 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 12b-25
NOTIFICATION OF LATE FILING
| (Check One): | þ | Form 10-K | o | Form 20-F | o | Form 10-Q | ||||||||
| o | Form N-CSR | o | Form N-CSR | |||||||||||
| For Period Ended: | December 31, 2004 | |||||||||||||
| o | Transition Report on Form 10-K | o | Transition Report on Form 10-Q | |||||||||||
| o | Transition Report on Form 20-F | o | Transition Report on Form N-SAR | |||||||||||
| o | Transition Report on Form 11-K | |||||||||||||
| For the Transition Period Ended: | ||||||||||||||
Read attached instruction sheet before preparing form. Please print or type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the item(s) to
which the notification relates: _________________
___________________________________________________________________________________________________________________
PART I
REGISTRANT INFORMATION
ANTIGENICS INC. |
||
Full name of registrant |
||
Former name if applicable |
||
630 Fifth Avenue, Suite 2100 |
||
Address of principal executive office (Street and number) |
||
New York, NY 10111 |
||
City, state and zip code |
||
PART II
RULE 12b-25 (b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate).
| (a) | The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense. | ||||
þ |
(b) | The subject annual report,
semi-annual report, transition report on Form 10-K, Form 20-F, Form
11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
|||
| (c) | The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III
NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
The Registrant has been working diligently to complete its Annual Report on Form 10-K for the year ended December 31, 2004. At this time, the Registrant has not had sufficient time, due to the incremental work required, to complete its evaluation of the effectiveness of its internal control over financial reporting, as such term is defined in Securities Exchange Act Rule 13a-15(f), required to be disclosed in its Annual Report on Form 10-K, without incurring unreasonable effort or expense. The Registrant expects to file its completed report by March 31, 2005.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this notification
| Peter Thornton | (212) | 994-8200 | ||
| (Name) | (Area Code) | (Telephone Number) | ||
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such short period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
þ Yes o No
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
o Yes þ No
If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
ANTIGENICS INC.
Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date: March 16, 2005
|
By | /s/ Peter Thornton |
||
| Peter Thornton | ||||
| Chief Financial Officer |